Resources & Publications

Dive into our posters, peer-reviewed publications, technical data, and case studies to see how Cypre’s 3D tumor models are advancing oncology drug discovery across the globe.

New to read

Making Waves Blog: AACR 2026

Cypre reviews the latest trends from AACR 2026, with a focus on next-generation modalities such as ADCs, bispecific antibodies, and in vivo cell therapies, as well as the New Approach Methodologies (NAMs) supporting these programs, including PDX or patient-derived organoids, organ-on-a-chip, and AI approaches.

Featured Resources

2025 AACR

At AACR this year, we debuted new datasets on NK cell therapy screening and MOA assessment on the Cypre Tumor Organoid Platform. Post-FDA's announcement, organoids and AI-enabled platforms were a highlight at the conference for Cypre, among an abundance of therapeutic data and precision medicine initiatives.

Featured Resources

2024 Antibody Engineering & Therapeutics

We are excited to share the latest data on screening checkpoint inhibitors (anti-PD1, anti-CTLA4), and a T cell engager (anti-CD3, anti-EpCAM), revealing their mechanism of action in the Cypre tumor microenvironment organoids and the data’s implications for cytokine release syndrome.

Featured Resources

2024 AACR Poster

Cypre presented its poster at AACR24: “Automated 42 PDX 3D in vitro tumor models of the TME screen immuno-oncology and targeted compounds and biologics for antitumor effects and MOA” on Tuesday, April 9th at 9am-noon in Section 28 (Poster 23, Abstract 4703).

2023 CELLS Publication

April 13, 2023: Cypre and Charles River publish a peer-reviewed manuscript detailing the Cypre 3D tumor platform, titled "A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies"

More Articles

Making Waves Blog: AACR 2026

Cypre reviews the latest trends from AACR 2026, with a focus on next-generation modalities such as ADCs, bispecific antibodies, and in vivo cell therapies, as well as the New Approach Methodologies (NAMs) supporting these programs, including PDX or patient-derived organoids, organ-on-a-chip, and AI approaches.

2026 AACR

Cypre attended the annual American Association of Cancer Research Conference in San Diego, meeting with partners and reviewing the latest trends in oncology therapeutic research. Next gen modalities like bispecific antibodies, ADCs, and in vivo cell therapies are advancing in pharma pipelines for their differentiated mechanism, reduced toxicity, and enhanced efficacy.

2026 JPM Conference

Cypre met with key leaders of the biopharmaceutical and life science industry on January 12-15. With the FDA's shift away from animal testing, there is considerable momentum to implement organoid and AI-driven approaches in drug discovery and safety assessment to advance the next generation of therapeutics.

2025 BIO Partnering Conference

Cypre was excited to attend this year's BIO Partnering Conference in Boston this June, the pre-eminent meeting for strategic discussions and deal-making in the biotechnology industry. Despite the macro challenges facing the market, partnering remains a core strategy for companies large and small to achieve our ultimate end goal - patient success.

Featured Resources

2025 AACR

At AACR this year, we debuted new datasets on NK cell therapy screening and MOA assessment on the Cypre Tumor Organoid Platform. Post-FDA's announcement, organoids and AI-enabled platforms were a highlight at the conference for Cypre, among an abundance of therapeutic data and precision medicine initiatives.

2025 JPM Healthcare Conference

Cypre's CEO, Kolin Hribar, PhD, was taking meetings with partners to advance the next generation of cancer therapeutics. Interested parties were encouraged to reach out to schedule a meeting.

Featured Resources

2024 Antibody Engineering & Therapeutics

We are excited to share the latest data on screening checkpoint inhibitors (anti-PD1, anti-CTLA4), and a T cell engager (anti-CD3, anti-EpCAM), revealing their mechanism of action in the Cypre tumor microenvironment organoids and the data’s implications for cytokine release syndrome.

Featured Resources

2024 AACR Poster

Cypre presented its poster at AACR24: “Automated 42 PDX 3D in vitro tumor models of the TME screen immuno-oncology and targeted compounds and biologics for antitumor effects and MOA” on Tuesday, April 9th at 9am-noon in Section 28 (Poster 23, Abstract 4703).

Eureka Blog Post

Our collaborator at Charles River, Julia Schüler, PhD DVM wrote a blog post titled Finally, Reliable Drug Screening Platforms for Lung Cancer Biomarkers, discussing the impact of 3D Tumor Models in screening patient-derived NSCLC tumors.

CRL Eureka Blog: Revolutionizing Oncology Drug Development

Cypre’s CEO, Kolin Hribar, was interviewed by the CRL Eureka blog on the future of oncology drug development, and how 3D models will play a central role in determining the next set of cancer immunotherapies.

Eureka Blog Post

November 30, 2023: Cypre Founder and CEO, Kolin Hribar, PhD, is interviewed by the Eureka Blog to discuss revolutionizing oncology drug development with translationally relevant 3D tumor models.

CRL Eureka Blog: The Trifecta of 3D Cancer Models

Charles River’s Oncology Therapeutic leader, Julia Schüler, writes about the impact of the Cypre 3D tumor platform in assaying the tumor microenvironment, stating ”We now have a platform for robust and repeatable screening using high-content image analysis. The hope is that this will rapidly identify a pipeline of effective therapies that hold up in the clinic and make it to patients.”

Q2 2023 Press Release

Cypre announces its 3D in vitro tumor models services and landmark publication detailing the platform for screening targeted and immunotherapy compounds and assessing novel immuno-modulatory insights.

Q1 2023 Press Release

Charles River launches press release ahead of AACR for its end-to-end Oncology Discovery capabilities, with the Cypre platform featured as a critical step for in vitro pharmacology and drug screening prior to IND.

2023 AACR Poster

Cypre presents a poster in collaboration with Charles River at the American Association for Cancer Research (AACR) conference titled “#1722 - KRAS, BRAF, BRCA1 and EGFR Mutation-Specific Panels Using Hydrogel-Based 3D In Vitro Tumor Models"

2023 CELLS Publication

April 13, 2023: Cypre and Charles River publish a peer-reviewed manuscript detailing the Cypre 3D tumor platform, titled "A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies"

2022 SITC Posters

Cypre presents posters at the Society for Immunotherapy Conference (SITC) titled “#299 3D in vitro Tumor microenvironment models for screening CAR-T cell therapy efficacy.” , “#1447 A 30 PDX Panel of 3D in vitro tumor models identifies responders”

Drug Discovery Today

Cypre presents a joint publication with Charles River titled “How to build a tumor: An industry perspective”

2022 AACR Poster

Cypre presented a joint poster with Charles River at AACR titled “#1880 - High throughput screening of 30 PDX cell lines in a 3D ECM hydrogel platform, incorporating tumor, stroma and immune components to demonstrate simultaneous investigation of multiple anti-tumor modalities”, highlighting the 3D Tumor Model Platform in screening 30 PDX models simulatenously with both small molecules and antibodies.

Webinar

Cypre co-presented an invited Endpoints webinar with Charles River titled “Change the Game: An Examination of Cutting-Edge Novel Oncology Screening Tools.” The webinar is now available on-demand through the link below.

Charles River Webinar

Cypre co-presented a webinar with Charles River titled “Predict Anticancer Efficacy with a New In Vitro 3D Modeling Platform”. The webinar is now available on-demand through the link below.

2021 AACR Poster

Cypre presented a joint poster with Charles River at AACR titled “3184 - 3D in vitro tumor model platform for screening patient-derived NSCLC, CRC, and RCC tumors with targeted therapy and immunotherapy”, highlighting the 3D Tumor Model Platform in screening PDX models with both small molecules and antibodies.

CRL Podcast

Charles River’s Chief Scientific Officer, Ian Waddell, PhD, sat down with Elizabeth Anderson, PhD, CRL’s Scientific Director of Oncology in a Vital Science™ Podcast hosted by Gina Mullane, Chief Marketing Officer, called “In Vitro 3D Models: A Blueprint for Drug Development”.

Featured Story

Our collaborators at Charles River have launched the joint service offering through their website, combining the CRL Tumor Model Compendium (PDX in vitro, ex vivo, cell lines) with Cypre’s 3D Tumor Model Platform to deliver translationally relevant 3D assays for cancer drug discovery.

Eureka Blog Post

Our collaborator at Charles River, Julia Schüler, PhD DVM, wrote a blog post with her colleague Elizabeth Anderson, PhD titled “Better In Vitro Cancer Models for Better Cancer Drugs” discussing Cypre’s Platform and its role in assaying the tumor microenvironment.

Partner Launch

Cypre and Charles River announce their strategic partnership to leverage Cypre’s 3D Tumor Model Platform with CRL’s genomically annotated and extensively characterized PDX Tumor Model Compendium.

Webinar – Charles River

Cypre co-presented a webinar with Charles River titled “Predict Anticancer Efficacy with a New In Vitro 3D Modeling Platform”. The webinar is now available on-demand through the link below.

2019 AACR Presentation

We presented a minisymposium talk alongside our collaborators at Genentech called “An in vitro 3D immune exclusion tumor model engineered in a layer-by-layer fashion”, highlighting our platform’s application in creating the immune excluded phenotype with mouse cells and assaying T cell infiltration through our ECM hydrogel, VersaGel®, and subsequent T cell-mediated killing.

Research Publication

We published a peer-reviewed research paper with our collaborators at Cedars Sinai Medical Center and Stanford, called “A Simple Three-dimensional Hydrogel Platform Enables Ex Vivo Cell Culture of Patient and PDX Tumors for Assaying Their Response to Clinically Relevant Therapies”, highlighting the utility of our technology in screening patient-derived tumors against small molecules.

No Results Found

Your search criteria may be too narrow. Try removing some filters!

Clear all Filters Contact us